[Skip to Content]
[Skip to Content Landing]
July 8, 1998

Corticosteroid Therapy in Acute Respiratory Distress SyndromeBetter Late Than Never?

Author Affiliations

From the Service de Réanimation Médicale (Drs Brun-Buisson and Brochard) and the Institut National de la Santé et de la Recherche Médicale (INSERM) U492 (Dr Brochard), Hôpital Henri Mondor, AP-HP, and Université Paris-XII, Créteil, France.

JAMA. 1998;280(2):182-183. doi:10.1001/jama.280.2.182

The annual incidence of acute respiratory distress syndrome (ARDS) has been estimated at 150000 cases in the United States.1 Although its outcome may have improved in the past 2 decades,2,3 ARDS remains associated with a very high mortality, ranging from 35% to 65% of affected patients.2,4 Severe hypoxemia (ie, an oxygenation ratio of PaO2 to fraction of inspired oxygen [FIO2] of <200) is the hallmark of the syndrome,1 but most fatalities result from associated conditions, especially multiple organ failure and sepsis, and less commonly from intractable respiratory failure.2

First Page Preview View Large
First page PDF preview
First page PDF preview